The GRFS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GRFS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The GRFS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View GRFS Detailed Price Forecast - CNN Money||View GRFS Detailed Summary - Google Finance|
|View GRFS Detailed Summary - Yahoo! Finance||View GRFS Stock Research & Analysis - Zacks.com|
|View GRFS Trends & Analysis - Trade-Ideas||View GRFS Major Holders - Barrons|
|View GRFS Call Transcripts - NASDAQ||View GRFS Breaking News & Analysis - Seeking Alpha|
|View GRFS Annual Report - CompanySpotlight.com||View GRFS OTC Short Report - OTCShortReport.com|
|View GRFS Fundamentals - TradeKing||View GRFS SEC Filings - Bar Chart|
|View Historical Prices for GRFS - The WSJ||View Performance/Total Return for GRFS - Morningstar|
|View the Analyst Estimates for GRFS - MarketWatch||View the Earnings History for GRFS - CNBC|
|View the GRFS Earnings - StockMarketWatch||View GRFS Buy or Sell Recommendations - MacroAxis|
|View the GRFS Bullish Patterns - American Bulls||View GRFS Short Pain Metrics - ShortPainBot.com|
|View GRFS Stock Mentions - StockTwits||View GRFS Stock Mentions - PennyStockTweets|
|View GRFS Stock Mentions - Twitter||View GRFS Investment Forum News - Investor Hub|
|View GRFS Stock Mentions - Yahoo! Message Board||View GRFS Stock Mentions - Seeking Alpha|
|View Insider Transactions for GRFS - SECform4.com||View Insider Transactions for GRFS - Insider Cow|
|View GRFS Major Holdings Summary - CNBC||View Insider Disclosure for GRFS - OTC Markets|
|View Insider Transactions for GRFS - Yahoo! Finance||View Institutional Holdings for GRFS - NASDAQ|
|View GRFS Stock Insight & Charts - FinViz.com||View GRFS Investment Charts - StockCharts.com|
|View GRFS Stock Overview & Charts - BarChart||View GRFS User Generated Charts - Trading View|
A Look At The Fair Value Of Grifols SA (BME:GRF)
Posted on Thursday December 06, 2018
I am going to run you through how I calculated the intrinsic value of Grifols SA (BME:GRF) by taking the foreast future cash flows of the company and discounting them Read More...
Shanghai RAAS in tie-up talks with U.S. blood products arm of Spain's Grifols
Posted on Thursday November 22, 2018
China's Shanghai RAAS Blood Products Co Ltd is in talks to combine with a U.S. subsidiary of Spanish blood products company Grifols, the two companies said. Grifols said the talks could lead to it exchanging Grifols Diagnostic Solutions Inc, which it said was valued at around $5 billion, for newly-issued Shanghai RAAS shares. Grifols would have strategic direction of the business.
BRIEF-Shanghai RAAS Blood Products Plans To Acquire Tiancheng (Germany), Spain's Grifols Diagnostic Solutions
Posted on Thursday November 22, 2018
Nov 22 (Reuters) - Shanghai RAAS Blood Products Co Ltd : * SAYS IT PLANS TO BUY TIANCHENG (GERMANY), WHICH OWNS ABOUT 90 PERCENT OF BIOTEST AG, FOR 589 MILLION EUROS (NOT TO BUY GERMANY'S BIOTEST FOR 589 ...
Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer's disease using its AMBAR treatment protocol
Posted on Saturday October 27, 2018
- AMBAR, an innovative treatment approach for Alzheimer's disease (AD) using plasma science has demonstrated, with statistical significance, the ability to slow down the progression of the disease in moderate AD patients. BARCELONA, Spain, Oct. 27, 2018 /PRNewswire/ -- Presenting the study results, Antonio Páez, M.D., Grifols Medical Director and Head of the AMBAR Clinical Program confirmed that the analysis of AMBAR data in moderate patients has shown positive, highly relevant results in a cohort of patients suffering from moderate Alzheimer's disease.